Cargando…
Moderate hypofractionation for prostate cancer
The biologic effects of changing the daily radiation dose (fractionation) have been studied for more than a century. The fractionation question in the treatment of prostate cancer came into stark relief in 1999 with the publication of a provocative report suggesting that hypofractionated regimens co...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043742/ https://www.ncbi.nlm.nih.gov/pubmed/30050793 http://dx.doi.org/10.21037/tau.2017.12.07 |
_version_ | 1783339346762399744 |
---|---|
author | Lee, W. Robert Koontz, Bridget F. |
author_facet | Lee, W. Robert Koontz, Bridget F. |
author_sort | Lee, W. Robert |
collection | PubMed |
description | The biologic effects of changing the daily radiation dose (fractionation) have been studied for more than a century. The fractionation question in the treatment of prostate cancer came into stark relief in 1999 with the publication of a provocative report suggesting that hypofractionated regimens could maintain the therapeutic ratio with logistic and financial advantages. In the last two decades medical evidence, weak and strong, has accumulated on the efficacy and toxicity of hypofractionated regimens in the radiotherapeutic treatment of prostate cancer. This brief review will focus on the results of randomized trials that compare moderate hypofractionation (HF) to conventional fractionation (CF). Extreme HF is covered in a separate review within this issue. |
format | Online Article Text |
id | pubmed-6043742 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-60437422018-07-26 Moderate hypofractionation for prostate cancer Lee, W. Robert Koontz, Bridget F. Transl Androl Urol Review Article The biologic effects of changing the daily radiation dose (fractionation) have been studied for more than a century. The fractionation question in the treatment of prostate cancer came into stark relief in 1999 with the publication of a provocative report suggesting that hypofractionated regimens could maintain the therapeutic ratio with logistic and financial advantages. In the last two decades medical evidence, weak and strong, has accumulated on the efficacy and toxicity of hypofractionated regimens in the radiotherapeutic treatment of prostate cancer. This brief review will focus on the results of randomized trials that compare moderate hypofractionation (HF) to conventional fractionation (CF). Extreme HF is covered in a separate review within this issue. AME Publishing Company 2018-06 /pmc/articles/PMC6043742/ /pubmed/30050793 http://dx.doi.org/10.21037/tau.2017.12.07 Text en 2018 Translational Andrology and Urology. All rights reserved. |
spellingShingle | Review Article Lee, W. Robert Koontz, Bridget F. Moderate hypofractionation for prostate cancer |
title | Moderate hypofractionation for prostate cancer |
title_full | Moderate hypofractionation for prostate cancer |
title_fullStr | Moderate hypofractionation for prostate cancer |
title_full_unstemmed | Moderate hypofractionation for prostate cancer |
title_short | Moderate hypofractionation for prostate cancer |
title_sort | moderate hypofractionation for prostate cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043742/ https://www.ncbi.nlm.nih.gov/pubmed/30050793 http://dx.doi.org/10.21037/tau.2017.12.07 |
work_keys_str_mv | AT leewrobert moderatehypofractionationforprostatecancer AT koontzbridgetf moderatehypofractionationforprostatecancer |